The abstract is read at the publisher; the summary is JClub's.
Sodium-glucose cotransporter 2 inhibitors slow chronic kidney disease progression, and a unifying framework links this to metabolic unloading of proximal tubule energetics beyond glycemic and hemodynamic effects.
- Why it matters: Kidney outcome trials show consistent renoprotection in both diabetic and non-diabetic chronic kidney disease, but the mechanistic basis is incompletely defined.
- What they did: This review synthesizes evidence that SGLT2i reduce ATP-dependent transport workload and oxygen consumption in proximal tubule cells, with possible effects on megalin-dependent endocytosis and downstream mitochondrial, redox, and autophagy/mitophagy pathways.
- The result: By mitigating energetic stress, the framework suggests tubular cells shift away from maladaptive hypertrophy and fibrosis toward adaptive repair, supporting disease-agnostic, early-initiation strategies and energetics-associated biomarkers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.